H-Guard Guards Hearts

The UK has made a £500 investment in Invizius' H-Guard—a product that aims to reduce the risk of heart disease by coating dialyzer fibers with an anti-inflamatory “primer” to make them more biocompatible.

Read the full article » | Posted 05-11-2018

Related Articles

• The Lancet Digital Health published results of Humacyte’s Phase III clinical trial of its V007 acellular tissue engineered vessel (ATEV) HD access Posted 09-18-2026
• Humacyte, Inc. announced Robert J. Kossman, MD, FACP, FASN and Prabir Roy-Chaudhury, MD, PhD, FASN have joined the company as advisors. Posted 08-21-2026
• Byonyks on the Move: X-2 and X-3 APD Devices in Development Posted 07-16-2026
• Dr. Ben Reynolds and the Virtual Reality Kidney Dialysis Training Project Posted 06-17-2026